# ATEMPT 2.0: Adjuvant T-DM1 vs TH

> **NCT04893109** · PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 500 (estimated)

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** trastuzumab-emtansine
- **DRUG:** Trastuzumab SC
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04893109
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-16
- **Primary completion:** 2026-11-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04893109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04893109, "ATEMPT 2.0: Adjuvant T-DM1 vs TH". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04893109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*